Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
210

Summary

Conditions
  • Alzheimer's Disease
  • Mild Cognitive Impairment
  • Post Traumatic Stress Disorder
  • Traumatic Brain Injury
Type
Observational
Design
Observational Model: CohortTime Perspective: Prospective

Participation Requirements

Age
Between 50 years and 90 years
Gender
Both males and females

Description

The overall long-term goal of this project is to prevent AD, which affects almost 50% of the US population over 85 years of age, and is the most common cause of dementia. Clinical signs and symptoms of AD include cognitive impairments, especially memory and emotional disturbances. In order to accomp...

The overall long-term goal of this project is to prevent AD, which affects almost 50% of the US population over 85 years of age, and is the most common cause of dementia. Clinical signs and symptoms of AD include cognitive impairments, especially memory and emotional disturbances. In order to accomplish this goal of prevention, a population at risk must be identified. Evidence suggests that both TBI and PTSD increase risk for cognitive decline, AD, and dementia. TBI and PTSD are common problems resulting from military service. Thus far, there have been no prospective studies using imaging and biomarkers, which directly measure changes in the brain and AD pathology to study the effects of TBI and PTSD. This proposed study will provide novel data to test these hypotheses. The results will have major implications for identifying, subjects at increased risk for AD, a possible need for early detection of AD in military Veterans with histories of TBI and PTSD, and a possible need to employ prevention and treatment measures to avoid accelerated development of AD in US military Veterans. This study is a first step toward a larger, more comprehensive study of dementia risk factors in Veterans. The results will lead to a design and statistical powering of a prevention trial. Therefore, this project could be the first step toward the prevention of AD in Veterans, and in the general population.

Tracking Information

NCT #
NCT01687153
Collaborators
  • United States Department of Defense
  • Telemedicine & Advanced Technology Research Center
  • Northern California Institute of Research and Education
  • San Francisco Veterans Affairs Medical Center
  • Alzheimer's Therapeutic Research Institute
Investigators
Study Director: Michael W. Weiner, MD University of California, San Francisco Principal Investigator: Paul Aisen, MD USC Alzheimer's Therapeutic Research Institute (ATRI) Principal Investigator: Ronald Petersen, MD, PhD Mayo Clinic